Literature DB >> 1618692

Absence of HTLV-II co-infection in HTLV-I-associated myelopathy patients.

K Miyamoto1, T Nakamura, S Nagataki, N Tomita, K Kitajima.   

Abstract

Syncytium inhibition assay to distinguish between HTLV-I and HTLV-II infection was performed with sera and cerebrospinal fluid of 15 HTLV-I-associated myelopathy (HAM) patients. Also, genome analysis of HTLV-II proviral DNA was performed in some HAM patients by use of the polymerase chain reaction method. All of the HAM patients were negative for co-infection with HTLV-II.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1618692      PMCID： PMC5918854          DOI： 10.1111/j.1349-7006.1992.tb01943.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN： 0910-5050


  15 in total

1.  High rate of HTLV-II infection in seropositive i.v. drug abusers in New Orleans.

Authors:  H Lee; P Swanson; V S Shorty; J A Zack; J D Rosenblatt; I S Chen
Journal:  Science       Date:  1989-04-28       Impact factor: 47.728

2.  HTLV-II in patients with HTLV-I-associated myelopathy.

Authors:  J Kira; Y Koyanagi; T Hamakado; Y Itoyama; N Yamamoto; I Goto
Journal:  Lancet       Date:  1991-07-06       Impact factor: 79.321

3.  Lack of anti-HTLV-II seropositivity in HTLV-I-associated myelopathy and adult T-cell leukaemia.

Authors:  T Kiyokawa; K Yamaguchi; Y Nishimura; K Yoshiki; K Takatsuki
Journal:  Lancet       Date:  1991-08-17       Impact factor: 79.321

4.  HTLV-I associated myelopathy, a new clinical entity.

Authors:  M Osame; K Usuku; S Izumo; N Ijichi; H Amitani; A Igata; M Matsumoto; M Tara
Journal:  Lancet       Date:  1986-05-03       Impact factor: 79.321

5.  Isolation of human T-cell lymphotropic virus type 2 from Guaymi Indians in Panama.

Authors:  M D Lairmore; S Jacobson; F Gracia; B K De; L Castillo; M Larreategui; B D Roberts; P H Levine; W A Blattner; J E Kaplan
Journal:  Proc Natl Acad Sci U S A       Date:  1990-11       Impact factor: 11.205

6.  Pseudotypes of human T-cell leukemia virus types 1 and 2: neutralization by patients' sera.

Authors:  P Clapham; K Nagy; R A Weiss
Journal:  Proc Natl Acad Sci U S A       Date:  1984-05       Impact factor: 11.205

7.  Prevalence of human T-cell leukemia/lymphoma virus (HTLV) type II infection among high-risk individuals: type-specific identification of HTLVs by polymerase chain reaction.

Authors:  G D Ehrlich; J B Glaser; K LaVigne; D Quan; D Mildvan; J J Sninsky; S Kwok; L Papsidero; B J Poiesz
Journal:  Blood       Date:  1989-10       Impact factor: 22.113

8.  Detection of provirus in an HTLV-II producer CD8+ T cell line by polymerase chain reaction combined with digoxigenin-ELISA method.

Authors:  K Miyamoto; N Tomita; Y Ohtsuki; K Kitajima
Journal:  Jpn J Cancer Res       Date:  1990-04

9.  Transformation of animal cells with human T-cell leukemia virus type II.

Authors:  K Miyamoto; N Tomita; K Hayashi; T Akagi
Journal:  Jpn J Cancer Res       Date:  1990-08

10.  Transformation of CD8+ T-cells producing a strong cytopathic effect on CD4+ T-cells through syncytium formation by HTLV-II.

Authors:  K Miyamoto; T Kamiya; J Minowada; N Tomita; K Kitajima
Journal:  Jpn J Cancer Res       Date:  1991-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.